Stimulators and activators of soluble guanylate cyclase: Review and potential therapeutic indications

Critical Care Research and Practice

Volumn 2012, Issue , 2012, Pages

  Nossaman, Bobby ^a,b   Pankey, Edward ^b   Kadowitz, Philip ^b  

^a OCHSNER MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866078704     PISSN: 20901305     EISSN: 20901313     Source Type: Journal    
DOI: 10.1155/2012/290805     Document Type: Review

References (164)

1. Hardman J. G., Sutherland E. W., Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3',5'-monophosphate from guanosine trihosphate. Journal of Biological Chemistry 1969 244 23 6363 6370 2-s2.0-0014670941
2. Hardman J. G., Davis J. W., Sutherland E. W., Effects of some hormonal and other factors on the excretion of guanosine 3',5'-monophosphate and adenosine 3',5'-monophosphate in rat urine. Journal of Biological Chemistry 1969 244 23 6354 6362 2-s2.0-0014670944
3. Arnold W. P., Mittal C. K., Katsuki S., Murad F., Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proceedings of the National Academy of Sciences of the United States of America 1977 74 8 3203 3207 2-s2.0-0000707453 (Pubitemid 8180317)
4. McNamara D. B., Kadowitz P. J., Hyman A. L., Ignarro L. J., Adenosine 3', 5'-monophosphate formation by preparations of rat liver soluble guanylate cyclase activated with nitric oxide, nitrosyl ferroheme, S-nitrosothiols, and other nitroso compounds. Canadian Journal of Physiology and Pharmacology 1980 58 12 1446 1456 2-s2.0-0019302448 (Pubitemid 11146504)
5. Moncada S., Palmer R. M. J., Higgs E. A., The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988 12 4 365 372 2-s2.0-0023756850
6. Moncada S., Higgs E. A., Nitric oxide and the vascular endothelium. Handbook of Experimental Pharmacology 2006 176 213 254 2-s2.0-34247093334
7. Stone J. R., Marletta M. A., Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry 1996 35 4 1093 1099 2-s2.0-0030051847 10.1021/bi9519718 (Pubitemid 26050770)
8. Wedel B., Humbert P., Harteneck C., Foerster J., Malkewitz J., Bohme E., Schultz G., Koesling D., Mutation of His-105 in the β 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proceedings of the National Academy of Sciences of the United States of America 1994 91 7 2592 2596 2-s2.0-0028179765
9. Ignarro L. J., Degnan J. N., Baricos W. H., Kadowitz P. J., Wolin M. S., Activation of purified guanylate cyclase by nitric oxide requires heme comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochimica et Biophysica Acta 1982 718 1 49 59 2-s2.0-0020485917
10. Craven P. A., DeRubertis F. R., Requirement for heme in the activation of purified guanylate cyclase by nitric oxide. Biochimica et Biophysica Acta 1983 745 3 310 321 2-s2.0-0021114825
11. Vincent S. R., Nitric oxide neurons and neurotransmission. Progress in Neurobiology 2010 90 2 246 255 2-s2.0-76849101595 10.1016/j.pneurobio.2009.10. 007
12. Domek-opaciska K., kdomek@cmdik.pan.pl Strosznajder J. B., Cyclic GMP metabolism and its role in brain physiology. Journal of Physiology and Pharmacology 2005 56, supplement 2 15 34 (Pubitemid 44933666)
13. Gruetter C. A., Barry B. K., McNamara D. B., Gruetter D. Y., Ignarro L., Kadowitz P. J., Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. Journal of Cyclic Nucleotide Research 1979 5 3 211 224 2-s2.0-0018311634 (Pubitemid 9246716)
14. Ignarro L. J., Harbison R. G., Wood K. S., Kadowitz P. J., Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. Journal of Pharmacology and Experimental Therapeutics 1986 236 1 30 36 2-s2.0-0022658167 (Pubitemid 16186120)
15. Busse R., Luckhoff A., Bassenge E., Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-Schmiedeberg's Archives of Pharmacology 1987 336 5 566 571 2-s2.0-0023635155 (Pubitemid 17166847)
16. Barber A. J., Cyclic nucleotides and platelet aggregation: effect of aggregating agents on the activity of cyclic nucleotide metabolizing enzymes. Biochimica et Biophysica Acta 1976 444 2 579 595 2-s2.0-0017160802
17. Mellion B. T., Ignarro L. J., Myers C. B., Inhibition of human platelet aggregation by S-nitrosothiols: heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Molecular Pharmacology 1983 23 3 653 664 (Pubitemid 13089783)
18. Mellion B. T., Ignarro L. J., Ohlstein E. H., Pontecorvo E. G., Hyman A. L., Kadowitz P. J., Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981 57 5 946 955 (Pubitemid 11096489)
19. Katsuki S., Arnold W., Mittal C., Murad F., Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. Journal of Cyclic Nucleotide Research 1977 3 1 23 35 2-s2.0-0017365359 (Pubitemid 8078230)
20. Kimura H., Mittal C. K., Murad F., Activation of guanylate cyclase from rat liver and other tissues by sodium azide. Journal of Biological Chemistry 1975 250 20 8016 8022 2-s2.0-0016698236
21. Mittal C. K., Kimura H., Murad F., Requirement for a macromolecular factor for sodium azide activation of guanylate cyclase. Journal of Cyclic Nucleotide Research 1975 1 5 261 269 2-s2.0-0016717717
22. Katsuki S., Arnold W. P., Murad F., Effects of sodium nitroprusside, nitroglycerin, and sodium azide on levels of cyclic nucleotides and mechanical activity of various tissues. Journal of Cyclic Nucleotide Research 1977 3 4 239 249 2-s2.0-0017695332 (Pubitemid 8187566)
23. Criss W. E., Murad F., Kimura H., Properties of guanylate cyclase from rat kidney cortex and transplantable kidney tumors. Journal of Cyclic Nucleotide Research 1976 2 1 11 19 2-s2.0-0017261336
24. Deguchi T., Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. Journal of Biological Chemistry 1977 252 21 7617 7619 2-s2.0-0017699160 (Pubitemid 8227338)
25. Garbers D. L., Suddath J. L., Hardman J. G., Enzymatic formation of inosine 3',5' monophosphate and of 2' deoxyguanosine 3',5' monophosphate: inosinate and deoxyguanylate cyclase activity. Biochimica et Biophysica Acta 1975 377 1 174 185 2-s2.0-0016431380
26. Kimura H., Murad F., Localization of particulate guanylate cyclase in plasma membranes and microsomes of rat liver. Journal of Biological Chemistry 1975 250 12 4810 4817 2-s2.0-0016837836
27. Busse E., Proof of guanylate cyclase activity in the coronary artery of cattle. Acta Biologica et Medica Germanica 1976 35 12 1595 1601 (Pubitemid 8116564)
28. Deguchi T., Amano E., Nakane M., Subcellular distribution and activation by non ionic detergents of guanylate cyclase in cerebral cortex of rat. Journal of Neurochemistry 1976 27 5 1027 1034 2-s2.0-0017199192
29. Deguchi T., Activation of guanylate cyclase in cerebral cortex of rat by hydroxylamine. Journal of Biological Chemistry 1977 252 2 596 601 2-s2.0-0017337366 (Pubitemid 8028880)
30. Mahaffee D. D., Ontjes D. A., Properties of adenylate cyclase solubilized from rat adrenal membranes: effects of ACTH and other stimulators on solubilization. Journal of Cyclic Nucleotide Research 1977 3 5 325 334 2-s2.0-0017663405 (Pubitemid 8246508)
31. Nilsson K. B., Andersson G. G., Effects of carbachol and calcium on the cyclic guanosine 3',5' monophosphate (cyclic GMP) metabolism in intestinal smooth muscle. Acta Physiologica Scandinavica 1977 99 2 246 253 2-s2.0-0017325407 (Pubitemid 8054993)
32. Katsuki S., Murad F., Regulation of adenosine cyclic 3',5' monophosphate and guanosine cyclic 3',5' monophosphate levels and contractility in bovine tracheal smooth muscle. Molecular Pharmacology 1977 13 2 330 341 2-s2.0-0017333057 (Pubitemid 8076777)
33. Gruetter C. A., Kadowitz P. J., Ignarro L. J., Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Canadian Journal of Physiology and Pharmacology 1981 59 2 150 156 2-s2.0-0019448891 (Pubitemid 11152379)
34. Stasch J. P., Hobbs A. J., NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handbook of Experimental Pharmacology 2009 191 277 308 2-s2.0-61749096117 10.1007/978-3-540-68964-513
35. Straub A., Stasch J. P., Alonso-Alija C., Benet-Buchholz J., Ducke B., Feurer A., Fürstner C., NO-independent stimulators of soluble guanylate cyclase. Bioorganic and Medicinal Chemistry Letters 2001 11 6 781 784 2-s2.0-0035952993 10.1016/S0960-894X(01)00073-7 (Pubitemid 32230679)
36. Evgenov O. V., Pacher P., Schmidt P. M., Haskó G., Schmidt H. H. H. W., Stasch J. P., NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery 2006 5 9 755 768 2-s2.0-33748312096 10.1038/nrd2038 (Pubitemid 44323702)
37. Furchgott R. F., Zawadzki J. V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288 5789 373 376 2-s2.0-0019195506 (Pubitemid 11169009)
38. Ignarro L. J., Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters. Pharmaceutical Research 1989 6 8 651 659 2-s2.0-0024433791 (Pubitemid 19253875)
39. Ignarro L. J., Byrns R. E., Buga G. M., Wood K. S., Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circulation Research 1987 61 6 866 879 2-s2.0-0023518452 (Pubitemid 18004583)
40. Ignarro L. J., Harbison R. G., Wood K. S., Kadowitz P. J., Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. Journal of Pharmacology and Experimental Therapeutics 1986 237 3 893 900 2-s2.0-0022461711 (Pubitemid 16088110)
41. McMahon T. J., Hood J. S., Kadowitz P. J., Pulmonary vasodilator response to vagal stimulation is blocked by N(ω)-nitro-L-arginine methyl ester in the cat. Circulation Research 1992 70 2 364 369 2-s2.0-0026557207
42. Hauser B., Bracht H., Matejovic M., Radermacher P., Venkatesh B., Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesthesia and Analgesia 2005 101 2 488 498 2-s2.0-22944444837 10.1213/01.ANE.0000177117.80058.4D (Pubitemid 41045235)
43. Blitzer M. L., Loh E., Roddy M. A., Stamler J. S., Creager M. A., Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. Journal of the American College of Cardiology 1996 28 3 591 596 2-s2.0-0030248135 10.1016/S0735-1097(96)00218-5 (Pubitemid 26288638)
44. Bellan J. A., Minkes R. K., McNamara D. B., Kadowitz P. J., N(ω)-nitro-L-arginine selectively inhibits vasodilator responses to acetylcholine and bradykinin in cats. American Journal of Physiology 1991 260 3 H1025 H1029 2-s2.0-0025735712
45. McMahon T. J., Hood J. S., Bellan J. A., Kadowitz P. J., N(ω)-nitro-L-arginine methyl ester selectively inhibits pulmonary vasodilator responses to acetylcholine and bradykinin. Journal of Applied Physiology 1991 71 5 2026 2031 2-s2.0-0025934210
46. Panza J. A., Casino P. R., Kilcoyne C. M., Quyyumi A. A., Role of endothelium-derived nitric oxide in the abnormal endothelium- dependent vascular relaxation of patients with essential hypertension. Circulation 1993 87 5 1468 1474 2-s2.0-0027161713 (Pubitemid 23133089)
47. Lauer T., Preik M., Rassaf T., Strauer B. E., Deussen A., Feelisch M., Kelm M., Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proceedings of the National Academy of Sciences of the United States of America 2001 98 22 12814 12819 2-s2.0-0035940415 10.1073/pnas.221381098 (Pubitemid 33020027)
48. Quyyumi A. A., Dakak N., Andrews N. P., Gilligan D. M., Panza J. A., Cannon R. O. III, Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995 92 3 320 326 2-s2.0-0029142684
49. Luscher T. F., Endogenous and exogenous nitrates and their role in myocardial ischaemia. British Journal of Clinical Pharmacology 1992 34, supplement 1 29S 35S 2-s2.0-0026772531
50. Thatcher G. R. J., Nicolescu A. C., Bennett B. M., Toader V., Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radical Biology and Medicine 2004 37 8 1122 1143 2-s2.0-4644231576 10.1016/j.freeradbiomed.2004.06.013 (Pubitemid 39302540)
51. Schmidt H. H. H. W., Schmidt P. M., Stasch J. P., NO- and haem-independent soluble guanylate cyclase activators. Handbook of Experimental Pharmacology 2009 191 309 339 2-s2.0-61749100199 10.1007/978-3-540-68964-514
52. Priviero F. B. M., Webb R. C., Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. Journal of Cardiovascular Pharmacology 2010 56 3 229 233 2-s2.0-77957562992 10.1097/FJC.0b013e3181eb4e75
53. Mayer B., Beretta M., The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles. British Journal of Pharmacology 2008 155 2 170 184 2-s2.0-51349126026 10.1038/bjp.2008.263
54. Murrell W., Nitro-Glycerine in angina pectoris. The Lancet 1879 1 80 81
55. Brunton T. L., On the use of nitrite of amyl in angina pectoris. The Lancet 1867 90 2291 97 98 2-s2.0-50449171019
56. Bogaert M. G., Organic nitrates in angina pectoris. Archives Internationales de Pharmacodynamie et de Therapie 1972 196, supplement 196 125 2-s2.0-0015328166
57. Battock D. J., Levitt P. W., Steele P. P., Effects of isosorbide dinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease. American Heart Journal 1976 92 4 455 458 2-s2.0-0017180948
58. Silber S., Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. European Journal of Clinical Pharmacology 1990 38, supplement 1 S35 S51 2-s2.0-0025373475 (Pubitemid 20140978)
59. Parker J. A., Organic nitrates: new formulations and their clinical advantages. American Journal of Cardiology 1996 77 13 38C 40C 2-s2.0-0029990489
60. Artz J. D., Schmidt B., McCracken J. L., Marletta M. A., Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance. Journal of Biological Chemistry 2002 277 21 18253 18256 2-s2.0-0037166299 10.1074/jbc.C200170200 (Pubitemid 34952368)
61. Beretta M., Gruber K., Kollau A., Russwurm M., Koesling D., Goessler W., Wing M. K., Schmidt K., Mayer B., Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases. Journal of Biological Chemistry 2008 283 26 17873 17880 2-s2.0-49649123367 10.1074/jbc.M801182200
62. Casey D. B., Badejo A. M. Jr., Dhaliwal J. S., Murthy S. N., Hyman A. L., Nossaman B. D., Kadowitz P. J., Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. American Journal of Physiology 2009 296 2 H524 H533 2-s2.0-61949204559 10.1152/ajpheart.00543.2008
63. Ignarro L. J., Napoli C., Loscalzo J., Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circulation Research 2002 90 1 21 28 2-s2.0-0037059510 10.1161/hh0102.102330 (Pubitemid 34074604)
64. Johnson J. B., Fairley A., Carter C., Effects of sublingual nitroglycerin on pulmonary arterial pressure in patients with left ventricular failure. Annals of Internal Medicine 1959 50 1 34 42 2-s2.0-70449238938
65. Fremont R. E., The actions of organic nitrates on the cardiopulmonary and peripheral circulations. Angiology 1961 12 391 400 2-s2.0-25644454558
66. Mikulic E., Franciosa J. A., Cohn J. N., Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure. Circulation 1975 52 3 477 482 2-s2.0-0016744302
67. Charuzi Y., Use of nitroglycerin ointment in acute pulmonary edema and hypertension. Chest 1982 82 6 800 2-s2.0-0020423652 (Pubitemid 13220895)
68. Palevsky H. I., Fishman A. P., Vasodilator therapy for primary pulmonary hypertension. Annual Review of Medicine 1985 36 563 578 2-s2.0-0021905993
69. Bundgaard H., Boesgaard S., Mortensen S. A., Arendrup H., Aldershvile J., Effect of nitroglycerin in patients with increased pulmonary vascular resistance undergoing cardiac transplantation. Scandinavian Cardiovascular Journal 1997 31 6 339 342 2-s2.0-0031449301 (Pubitemid 28010710)
70. Pearlman A. S., Engler R. L., Goldstein R. A., Kent K. M., Epstein S. E., Relative effects of nitroglycerin and nitroprusside during experimental acute myocardial ischemia. European Journal of Cardiology 1980 11 4 295 313 2-s2.0-0018887766 (Pubitemid 10083119)
71. GISSI-3 Investigators, GISSI-3: effects of lisinopril and transdermal glyceryl binitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. The Lancet 1994 343 8906 1115 1122
72. Jugdutt B. I., Nitrates in myocardial infarction. Cardiovascular Drugs and Therapy 1994 8 4 635 646 2-s2.0-0028072793 10.1007/BF00877417 (Pubitemid 24336466)
73. Lippton H. L., Gruetter C. A., Ignarro L. J., Meyer R. L., Kadowitz P. J., Vasodilator actions of several N-nitroso compounds. Canadian Journal of Physiology and Pharmacology 1982 60 1 68 75 (Pubitemid 12184134)
74. Ignarro L. J., Lippton H., Edwards J. C., Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-Nitrosothiols as active intermediates. Journal of Pharmacology and Experimental Therapeutics 1981 218 3 739 749 (Pubitemid 11005147)
75. Ignarro L. J., Gruetter C. A., Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochimica et Biophysica Acta 1980 631 2 221 231 2-s2.0-0019313372 (Pubitemid 10018147)
76. Kojda G., Patzner M., Hacker A., Noack E., Nitric oxide inhibits vascular bioactivation of glyceryl trinitrate: a novel mechanism to explain preferential venodilation of organic nitrates. Molecular Pharmacology 1998 53 3 547 554 2-s2.0-0031977184 (Pubitemid 28162879)
77. Chen Z., Zhang J., Stamler J. S., Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proceedings of the National Academy of Sciences of the United States of America 2002 99 12 8306 8311 2-s2.0-0037062518 10.1073/pnas.122225199 (Pubitemid 34651048)
78. Murad F., Mittal C. K., Arnold W. P., Katsuki S., Kimura H., Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Advances in Cyclic Nucleotide Research 1978 9 145 158 2-s2.0-0017869566
79. Needleman P., Jakschik B., Johnson E. M. Jr., Sulfhydryl requirement for relaxation of vascular smooth muscle. Journal of Pharmacology and Experimental Therapeutics 1973 187 2 324 331 2-s2.0-0015713177
80. Needleman P., Organic nitrate metabolism. Annual Review of Pharmacology and Toxicology 1976 16 81 93 2-s2.0-0016912118
81. Needleman P., Johnson E. M. Jr., Mechanism of tolerance development to organic nitrates. Journal of Pharmacology and Experimental Therapeutics 1973 184 3 709 715 2-s2.0-0015595425
82. Tsuchida S., Maki T., Sato K., Purification and characterization of glutathione transferases with an activity toward nitroglycerin from human aorta and heart: multiplicity of the human class Mu forms. Journal of Biological Chemistry 1990 265 13 7150 7157 2-s2.0-0025357203
83. Yeates R. A., Schmid M., Leitold M., Antagonism of glycerol trinitrate activity by an inhibitor of glutathione S-transferase. Biochemical Pharmacology 1989 38 11 1749 1753 2-s2.0-0024390285 (Pubitemid 19138523)
84. Millar T. M., Stevens C. R., Benjamin N., Eisenthal R., Harrison R., Blake D. R., Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Letters 1998 427 2 225 228 2-s2.0-0032496394 10.1016/S0014-5793(98)00430-X (Pubitemid 28225062)
85. McDonald B. J., Bennett B. M., Cytochrome P-450 mediated biotransformation of organic nitrates. Canadian Journal of Physiology and Pharmacology 1990 68 12 1552 1557 2-s2.0-0025638838
86. McDonald B. J., Bennett B. M., Biotransformation of glyceryl trinitrate by rat aortic cytochrome P450. Biochemical Pharmacology 1993 45 1 268 270 2-s2.0-0027463904 10.1016/0006-2952(93)90403-J (Pubitemid 23023767)
87. Seth P., Fung H. L., Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochemical Pharmacology 1993 46 8 1481 1486 2-s2.0-0027501074 10.1016/0006-2952(93)90115-D (Pubitemid 23319320)
88. McGuire J. J., Anderson D. J., McDonald B. J., Narayanasami R., Bennett B. M., Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochemical Pharmacology 1998 56 7 881 893 2-s2.0-0032189899 10.1016/S0006-2952(98)00216-0 (Pubitemid 28458982)
89. Chen Z., Foster M. W., Zhang J., Mao L., Rockman H. A., Kawamoto T., Kitagawa K., Nakayama K. I., Hess D. T., Stamler J. S., An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proceedings of the National Academy of Sciences of the United States of America 2005 102 34 12159 12164 2-s2.0-24744461677 10.1073/pnas.0503723102 (Pubitemid 41291145)
90. Packer M., Lee W. H., Kessler P. D., Gottlieb S. S., Medina N., Yushak M., Prevention and reversal of nitrate tolerance in patients with congestive heart failure. The New England Journal of Medicine 1987 317 13 799 804 (Pubitemid 17136471)
91. Noack E., Feelisch M., Molecular mechanisms of nitrovasodilator bioactivation. Basic Research in Cardiology 1991 86, supplement 2 37 50 2-s2.0-0026042797
92. Núñez C., Víctor V. M., Tur R., Alvarez-Barrientos A., Moncada S., Esplugues J. V., D'Ocón P., Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circulation Research 2005 97 10 1063 1069 2-s2.0-27944477787 10.1161/01.RES.0000190588.84680.34 (Pubitemid 41668920)
93. Feelisch M., Kelm M., Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochemical and Biophysical Research Communications 1991 180 1 286 293 2-s2.0-0026009586 10.1016/S0006-291X(05)81290-2
94. Schror K., Forster S., Woditsch I., On-line measurement of nitric oxide release from organic nitrates in the intact coronary circulation. Naunyn-Schmiedeberg's Archives of Pharmacology 1991 344 2 240 246 2-s2.0-0025788856
95. Marks G. S., McLaughlin B. E., Nakatsu K., Brien J. F., Direct evidence for nitric oxide formation from glyceryl trinitrate during incubation with intact bovine pulmonary artery. Canadian Journal of Physiology and Pharmacology 1992 70 2 308 311 2-s2.0-0026511228
96. Chung S. J., Fung H. L., Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production: probes with inhibitors and tolerance development. Biochemical Pharmacology 1993 45 1 157 163 2-s2.0-0027528328 10.1016/0006-2952(93)90388-D (Pubitemid 23023752)
97. Feelisch M., Brands F., Kelm M., Human endothelial cells bioactivate organic nitrates to nitric oxide. Implications for the reinforcement of endothelial defence mechanisms. European Journal of Clinical Investigation 1995 25 10 737 745 2-s2.0-0028788144
98. Mulsch A., Bara A., Mordvintcev P., Vanin A., Busse R., Specificity of different organic nitrates to elicit NO formation in rabbit vascular tissues and organs in vivo. British Journal of Pharmacology 1995 116 6 2743 2749 2-s2.0-0028879994
99. Kuo W. N., Kocis J. M., Robinson M. J., Nibbs J., Nayar R., Further study on s-nitrosation by nitrite. Frontiers in Bioscience 2003 8 a143 a147 2-s2.0-1542569485 (Pubitemid 39069953)
100. Meyer D. J., Kramer H., Ketterer B., Human glutathione transferase catalysis of the formation of S-nitrosoglutathione from organic nitrites plus glutathione. FEBS Letters 1994 351 3 427 428 10.1016/0014-5793(94)00904-X (Pubitemid 24285350)
101. Zeng H., Spencer N. Y., Hogg N., Metabolism of S-nitrosoglutathione by endothelial cells. American Journal of Physiology 2001 281 1 H432 H439 2-s2.0-0034814314
102. Sarr M., Lobysheva I., Diallo A. S., Stoclet J. C., Schini-Kerth V. B., Muller B., Formation of releasable NO stores by S-nitrosoglutathione in arteries exhibiting tolerance to glyceryl-trinitrate. European Journal of Pharmacology 2005 513 1-2 119 123 2-s2.0-18844417423 10.1016/j.ejphar.2005.02.037 (Pubitemid 40692252)
103. Foster M. W., McMahon T. J., Stamler J. S., S-nitrosylation in health and disease. Trends in Molecular Medicine 2003 9 4 160 168 2-s2.0-0038136867 10.1016/S1471-4914(03)00028-5 (Pubitemid 36626705)
104. Caramori P. R. A., Adelman A. G., Azevedo E. R., Newton G. E., Parker A. B., Parker J. D., Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. Journal of the American College of Cardiology 1998 32 7 1969 1974 2-s2.0-0032420985 10.1016/S0735-1097(98)00456-2 (Pubitemid 29010463)
105. Azevedo E. R., Schofield A. M., Kelly S., Parker J. D., Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. Journal of the American College of Cardiology 2001 37 2 505 509 2-s2.0-0035133327 10.1016/S0735-1097(00)01140-2
106. Schulz E., Tsilimingas N., Rinze R., Reiter B., Wendt M., Oelze M., Woelken-Weckmüller S., Walter U., Reichenspurner H., Meinertz T., Münzel T., Functional and biochemical analysis of endothelial (Dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002 105 10 1170 1175 2-s2.0-0037066021 10.1161/hc1002.105186 (Pubitemid 34225816)
107. Napoli C., Ignarro L. J., Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Archives of Pharmacal Research 2009 32 8 1103 1108 2-s2.0-69949111623 10.1007/s12272-009-1801-1
108. Berkenboom G., Unger P., Fontaine J., Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators. Journal of Cardiovascular Pharmacology 1989 14, supplement 11 S35 S39 (Pubitemid 20313488)
109. Fish R. D., Nabel E. G., Selwyn A. P., Ludmer P. L., Mudge G. H., Kirshenbaum J. M., Schoen F. J., Alexander R. W., Ganz P., Responses of coronary arteries of cardiac transplant patients to acetylcholine. Journal of Clinical Investigation 1988 81 1 21 31 2-s2.0-0023906357 (Pubitemid 18092228)
110. Ko F. N., Wu C. C., Kuo S. C., Lee F. Y., Teng C. M., YC-1, a novel activator of platelet guanylate cyclase. Blood 1994 84 12 4226 4233 2-s2.0-0028109332
111. Wu C. C., Ko F. N., Kuo S. C., Lee F. Y., Teng C. M., YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. British Journal of Pharmacology 1995 116 3 1973 1978 2-s2.0-0029166002
112. Friebe A., Schultz G., Koesling D., Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. The EMBO Journal 1996 15 24 6863 6868 2-s2.0-0030476908 (Pubitemid 27023257)
113. Feelisch M., Kotsonis P., Siebe J., Clement B., Schmidt H. H. H. W., The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo-[4,3,-a]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Molecular Pharmacology 1999 56 2 243 253 2-s2.0-0032793679 (Pubitemid 29347599)
114. Bennett B. M., McDonald B. J., Nigam R., Simon W. C., Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends in Pharmacological Sciences 1994 15 7 245 249 2-s2.0-0028260356 10.1016/0165-6147(94)90319-0 (Pubitemid 24210730)
115. Mülsch A., Bauersachs J., Schäfer A., Stasch J.-P., Kast R., Busse R., Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. British Journal of Pharmacology 1997 120 4 681 689 10.1038/sj.bjp.0700982 (Pubitemid 27089418)
116. Teng C. M., Wu C. C., Ko F. N., Lee F. Y., Kuo S. C., YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. European Journal of Pharmacology 1997 320 2-3 161 166 2-s2.0-0031565271 10.1016/S0014-2999(96)00911-9 (Pubitemid 27076741)
117. Wegener J. W., Gath I., Förstermann U., Nawrath H., Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. British Journal of Pharmacology 1997 122 7 1523 1529 (Pubitemid 27503948)
118. Wu C.-C., Ko F.-N., Teng C.-M., Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochemical and Biophysical Research Communications 1997 231 2 412 416 10.1006/bbrc.1996.5998 (Pubitemid 27214323)
119. Straub A., alexander.straub.as@bayer-ag.de Benet-Buckholz J., Fröde R., Kern A., Kohlsdorfer C., Schmitt P., Schwarz T., Siefert H.-M., Stasch J.-P., Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorganic and Medicinal Chemistry 2002 10 6 1711 1717 10.1016/S0968-0896(02)00034-2 (Pubitemid 34286364)
120. Stasch J. P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., Straub A., Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. British Journal of Pharmacology 2002 135 2 333 343 2-s2.0-0036177297 (Pubitemid 34151165)
121. Stasch J. P., Becker E. M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Plei U., Schröder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M., NO-independent regulatory site on soluble guanylate cyclase. Nature 2001 410 6825 212 215 2-s2.0-0035826261 10.1038/35065611 (Pubitemid 32216593)
122. Evgenov O. V., Kohane D. S., Bloch K. D., Stasch J. P., Volpato G. P., Bellas E., Evgenov N. V., Buys E. S., Gnoth M. J., Graveline A. R., Liu R., Hess D. R., Langer R., Zapol W. M., Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. American Journal of Respiratory and Critical Care Medicine 2007 176 11 1138 1145 2-s2.0-36849026670 10.1164/rccm.200707-1121OC (Pubitemid 350223760)
123. Freitas C. F., Morganti R. P., Annichino-Bizzacchi J. M., De Nucci G., Antunes E., edson.antunes@uol.com.br Effect of bay 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. Clinical and Experimental Pharmacology and Physiology 2007 34 1-2 10 14 10.1111/j.1440-1681.2007.04524.x (Pubitemid 46069579)
124. Deruelle P., Grover T. R., Storme L., Abman S. H., Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. American Journal of Physiology 2005 288 4 L727 L733 2-s2.0-15544366091 10.1152/ajplung.00409.2004 (Pubitemid 40404141)
125. Deruelle P., Grover T. R., Abman S. H., Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. American Journal of Physiology 2005 289 5 L798 L806 2-s2.0-24644479957 10.1152/ajplung.00119.2005 (Pubitemid 41504411)
126. Deruelle P., Balasubramaniam V., Kunig A. M., Seedorf G. J., Markham N. E., Abman S. H., BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biology of the Neonate 2006 90 2 135 144 2-s2.0-33746933767 10.1159/000092518 (Pubitemid 44197481)
127. Badejo A. M. Jr., Nossaman V. E., Pankey E. A., Bhartiya M., Kannadka C. B., Murthy S. N., Nossaman B. D., Kadowitz P. J., Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. American Journal of Physiology 2010 299 4 H1153 H1159 2-s2.0-77958062082 10.1152/ajpheart.01101.2009
128. Evgenov O. V., Ichinose F., Evgenov N. V., Gnoth M. J., Falkowski G. E., Chang Y., Bloch K. D., Zapol W. M., Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004 110 15 2253 2259 2-s2.0-5644278742 10.1161/01.CIR.0000144469.01521.8A (Pubitemid 39372510)
129. Doggrell S. A., Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. Current Opinion in Investigational Drugs 2005 6 9 874 878 2-s2.0-24644489679 (Pubitemid 41269366)
130. Schmidt P., Schramm M., Schröder H., Stasch J.-P., Johannes-Peter.Stasch.JS@Bayer-ag.de Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. European Journal of Pharmacology 2003 468 3 167 174 10.1016/S0014-2999(03)01674-1 (Pubitemid 36712896)
131. Stasch J. P., Schmidt P., Alonso-Alija C., Apeler H., Dembowsky K., Haerter M., Heil M., Minuth T., Perzborn E., Pleiss U., Schramm M., Schroeder W., Schröder H., Stahl E., Steinke W., Wunder F., No- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. British Journal of Pharmacology 2002 136 5 773 783 2-s2.0-0035987790 (Pubitemid 34785720)
132. Mittendorf J., Weigand S., Alonso-Alija C., Bischoff E., Feurer A., Gerisch M., Kern A., Knorr A., Lang D., Muenter K., Radtke M., Schirok H.,
133. Frey R., Mück W., Unger S., Artmeier-Brandt U., Weimann G., Wensing G., Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. Journal of Clinical Pharmacology 2008 48 8 926 934 2-s2.0-47549110195 10.1177/0091270008319793 (Pubitemid 352009497)
134. Grimminger F., Weimann G., Frey R., Voswinckel R., Thamm M., Bölkow D., Weissmann N., Mück W., Unger S., Wensing G., Schermuly R. T., Ghofrani H. A., ardeschir.ghofrani@innere.med.uni-giessen.de First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. European Respiratory Journal 2009 33 4 785 792 10.1183/09031936.00039808
135. Ghofrani H. A., Hoeper M. M., Halank M., Meyer F. J., Staehler G., Behrf J., Ewert R., Weimann G., Grimminger F., Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal 2010 36 4 792 799 2-s2.0-77956664858 10.1183/09031936.00182909
136. Wolin M. S., Reactive oxygen species and the control of vascular function. American Journal of Physiology 2009 296 3 H539 H549 2-s2.0-64049083005 10.1152/ajpheart.01167.2008
137. Schmidt P. M., Schramm M., Schröder H., Wunder F., Stasch J. P., Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. Journal of Biological Chemistry 2004 279 4 3025 3032 2-s2.0-1642576030 10.1074/jbc.M310141200 (Pubitemid 38114295)
138. Schindler U., Strobel H., Schönafinger K., Linz W., Lohn M., Martorana P. A., Rutten H., Schindler P. W., Busch A. E., Sohn M., Töpfer A., Pistorius A., Jannek C., Mülsch A., muelsch@uni-mainz.de Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Molecular Pharmacology 2006 69 4 1260 1268 10.1124/mol.105.018747
139. Zhao Y., Brandish P. E., DiValentin M., Schelvis J. P. M., Babcock G. T., Marletta M. A., Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000 39 35 10848 10854 2-s2.0-0034609541 10.1021/bi9929296
140. Dierks E. A., Burstyn J. N., The deactivation of soluble guanylyl cyclase by redox-active agents. Archives of Biochemistry and Biophysics 1998 351 1 1 7 10.1006/abbi.1997.0408 (Pubitemid 28373043)
141. Schmidt K., Graier W. F., Kostner G. M., Mayer B., Bohme E., Kukovetz W. R., Oxidized low-density lipoprotein antagonizes the activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor but does not interfere with its biosynthesis. Cellular Signalling 1991 3 4 361 367 2-s2.0-0025830487 10.1016/0898-6568(91)90065-3 (Pubitemid 121006211)
142. Galle J., Mulsch A., Busse R., Bassenge E., Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arteriosclerosis and Thrombosis 1991 11 1 198 203
143. Craven P. A., DeRubertis F. R., Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins: evidence for involvement of the paramagnetic nitrosyl.heme complex in enzyme activation. Journal of Biological Chemistry 1978 253 23 8433 8443 2-s2.0-0018216365 (Pubitemid 9082547)
144. DeRubertis F. R., Craven P. A., Pratt D. W., Electron spin resonance study of the role of nitrosyl-heme in the activation of guanylate cyclase by nitrosoguanidine and related agonists. Biochemical and Biophysical Research Communications 1978 83 1 158 167 (Pubitemid 8378958)
145. Elkayam U., Roth A., Mehra A., Ostrzega E., Shotan A., Kulick D., Jamison M., Johnson J. V., Rahimtoola S. H., Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation 1991 84 5 2040 2048 2-s2.0-0026005802
146. Elkayam U., Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Annals of Internal Medicine 1991 114 8 667 677 2-s2.0-0025912301
147. Schwemmer M., Bassenge E., New approaches to overcome tolerance to nitrates. Cardiovascular Drugs and Therapy 2003 17 2 159 173 2-s2.0-0141540373 10.1023/A:1025343919959 (Pubitemid 37174690)
148. Dumitrascu R., Weissmann N., Ghofrani H. A., Dony E., Beuerlein K., Schmidt H., Stasch J. P., Gnoth M. J., Seeger W., Grimminger F., Schermuly R. T., Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006 113 2 286 295 2-s2.0-33644999416 10.1161/CIRCULATIONAHA.105.581405
149. Stasch J. P., Schmidt P. M., Nedvetsky P. I., Nedvetskaya T. Y., Arun Kumar H. S., Meurer S., Deile M., Taye A., Knorr A., Lapp H., Müller H., Turgay Y., Rothkegel C., Tersteegen A., Kemp-Harper B., Müller-Esterl W., Schmidt H. H. H. W., Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Journal of Clinical Investigation 2006 116 9 2552 2561 2-s2.0-33748302123 10.1172/JCI28371 (Pubitemid 44330154)
150. Boerrigter G., Costello-Boerrigter L. C., Cataliotti A., Lapp H., Stasch J. P., Burnett J. C. Jr., Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007 49 5 1128 1133 2-s2.0-34247238203 10.1161/HYPERTENSIONAHA.106.083832 (Pubitemid 351664312)
151. Thom S., Hughes A., Martin G., Sever P. S., Endothelium-dependent relaxation in isolated human arteries and veins. Clinical Science 1987 73 5 547 552 2-s2.0-0023575690 (Pubitemid 18019705)
152. McMahon T. J., Kadowitz P. J., Methylene blue inhibits neurogenic cholinergic vasodilator responses in the pulmonary vascular bed of the cat. American Journal of Physiology 1992 263 5 L575 L584 2-s2.0-0026462917
153. Casey D. B., Badejo A. M. Jr., Dhaliwal J. S., Sikora J. L., Fokin A., Golwala N. H., Greco A. J., Murthy S. N., Nossaman B. D., Hyman A. L., Kadowitz P. J., Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. American Journal of Physiology 2010 299 1 H184 H192 2-s2.0-77953786515 10.1152/ajpheart.00181.2009
154. Vuorinen P., Porsti I., Metsa-Ketela T., Manninen V., Vapaatalo H., Laustiola K. E., Modification of nitrovasodilator effects on vascular smooth muscle by exogenous GTP and guanosine. Journal of Cardiovascular Pharmacology 1991 18 6 871 877
155. Feng C. J., Cheng D. Y., Kaye A. D., Kadowitz P. J., Nossaman B. D., Influence of N(ω)-nitro-L-arginine methyl ester, LY83583, glybenclamide and L158809 on pulmonary circulation. European Journal of Pharmacology 1994 263 1-2 133 140 (Pubitemid 24290263)
156. Murthy S. N., Nossaman B. D., Kadowitz P. J., New approaches to the treatment of pulmonary hypertension: from bench to bedside. Cardiology in Review 2010 18 2 76 84 2-s2.0-77149165430 10.1097/CRD.0b013e3181cbcbf3
157. Pankey E. A., Bhartiya M., Badejo A. M. Jr., Haider U., Stasch J.-P., Murthy S. N., Nossaman B. D., Kadowitz P. J., pkadowi@tulane.edu Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. American Journal of Physiology 2011 300 3 H792 H802 10.1152/ajpheart.00953.2010
158. Korkmaz S., Radovits T., Barnucz E., Hirschberg K., Neugebauer P., Loganathan S., Veres G., Páli S., Seidel B., Zöllner S., Karck M., Szabó G., Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 2009 120 8 677 686 2-s2.0-69649087375 10.1161/CIRCULATIONAHA.109.870774
159. Radovits T., Korkmaz S., Miesel-Gröschel C., Seidel B., Stasch J. P., Merkely B., Karck M., Szabó G., Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. European Journal of Cardio-thoracic Surgery 2011 39 2 248 255 2-s2.0-77953829748 10.1016/j.ejcts.2010.05.025
160. Boerrigter G., Lapp H., Burnett J. C. Jr., burnett.john@mayo.edu Modulation of cGMP in heart failure: a new therapeutic paradigm. Handbook of Experimental Pharmacology 2009 191 485 506 10.1007/978-3-540-68964-521
161. Nossaman B. D., Akuly H. A., Lasker G. F., Nossaman V. E., Rothberg P. A., Kadowitz P. J., The reemergence of nitrite as a beneficial agent in the treatment of ischemic cardiovascular diseases. Asian Journal of Experimental Biological Sciences 2010 1 2 451 459
162. Nossaman V. E., Nossaman B. D., Kadowitz P. J., Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiology in Review 2010 18 4 190 197 2-s2.0-77954011631 10.1097/CRD.0b013e3181c8e14a
163. Frey R., Mück W., Unger S., Artmeier-Brandt U., Weimann G., Wensing G., Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. Journal of Clinical Pharmacology 2008 48 12 1400 1410 2-s2.0-57449087642 10.1177/0091270008322906
164. Lapp H., Mitrovic V., Franz N., Heuer H., Buerke M., Wolfertz J., Mueck W., Unger S., Wensing G., Frey R., Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009 119 21 2781 2788 2-s2.0-67649229211 10.1161/CIRCULATIONAHA. 108.800292